A Phase II Study to Evaluate the Efficacy of IdeS to Desensitize Transplant Patients With a Positive Crossmatch Test
Status:
Completed
Trial end date:
2018-07-03
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effectiveness of the study drug IdeS in patients
who are on the waiting list for kidney transplant and have previously undergone
desensitization unsuccessfully or in whom effective desensitization will be highly unlikely.
At study entry, the patients will have an available deceased or live donor with a positive
crossmatch test. The study will assess IdeS efficacy and safety in removing Donor Specific
Antibodies (DSAs) and thereby convert a positive crossmatch test to negative.